NE
Neuphoria Therapeutics Inc.
NEUP · NASDAQ
$3.71 -1.33% (-$0.05)
1M -6.08%
Market Cap $20.1M
P/E Ratio -
Div. Yield -
ROE 77.03%
Bulios Fair Price
$4.42
19.1% upside
Current Price
$3.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NEUP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/B 0.82x
P/S 17.08x
PEG N/A
Growth
100 /100
Growing Book val. growth 1,088.56%
Rev. growth N/A
FCF growth N/A
Profitability
17 /100
Weak FCF margin 1,052,120.00%
Op. margin 1,187.73%
Gross margin 43.54%
Quality
0 /100
Poor Asset turnover 0.04x
ROA 64.55%
ROIC 49.60%
Debt
100 /100
Low Current ratio 27.85x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
37 /100
Moderate EPS volatility 691.22%
Profitable years 0
Beta 0.75x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NEUP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Spyridon Papapetropoulos
Employees
8
Headquarters
Burlington